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ABSTRACT 
TRANSPLANTATION AMELIORATES THE HYPERCOAGULABILITY OF 
ENDSTAGE RENAL DISEASE 
Fred Aslan, Jane C K Fitch, Rex L Mahnensmith, Amy L Friedman. Department of 
Surgery, Yale University, School of Medicine, New Haven, CT. Department of 
Anesthesiology, Baylor University, School of Medicine, Houston, TX. 
It has been suggested that hypercoagulability associated with ESRD may be 
attributable to diminished circulating levels of antithrombin III (ATIII). Whole blood 
clotting and rheological assessment of blood, by thromboelastography (TEG) and 
Sonoclot (SCT) analyses, was performed on fresh specimens from 4 patient groups: 
control (C), hemodialysis (HD), peritoneal dialysis (PD) and well functioning kidney 
transplant recipients (Txp). TEG indices included r (rate of thromboplastin generation), 
r+k (coagulation time), Ang (rate of clot formation), MA (clot strength), LY30 and LY60 
(% fibrinolysis at 30 and 60 minutes). SCT indices included SonACT (activation time) 












MA 64.5 ± 5.4 77.2 ± 4.2 73.4 ±6.9 66.5 ± 13.8 <0.001 AUU 
Ang 68.3 ±8.8 74.1 ±5.6 74.6 ±4.7 64.1 ± 14.3 0.006 L U 
LY30 2.1 ± 1.8 0.7 ±0.9 1.3 ± 1.3 1.5 ± 1.9 0.036 
LY60 5.8 ±3.8 2.5 ±2.2 3.2 ±2.7 3.4 ±3.3 0.014 A 
SonR 16.3 ±4.3 32.4 ± 16.9 33.5 ±29.3 24.5 ±7.8 <0.001 B 
SonACT 118.8 ± 19.2 145.4 ±35.8 142.6 ±41.9 127.6 ±24.9 0.019 
ATIII 84.6 ± 19.4 69.7 ± 20.6 68.7 ±22.0 70.4 ± 22.3 0.049 
P<0.05: A=PD vs C B=HD vs C C=HD vs Txp D=PD vs Txp 
TEG and SCT measure quantitative and qualitative platelet and coagulation factor 
function. ESRD patients manifest thrombotic tendencies by TEG, SCT and ATIII levels. 
Txp appears to correct these values. Lowered levels of ATIII in both dialysis groups were 
not normalized post-transplant. It remains to be determined whether the benefits of 
transplant are attributed to platelet function or other coagulation factors. 
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Thrombotic complications in hemodialysis, peritoneal dialysis and kidney 
transplant patients 
Thrombosis is a common complication of patients on hemodialysis and 
continuous ambulatory peritoneal dialysis (CAPD)(1) as clinically evident by the 
frequent rate of vascular access thrombosis which costs the United States $1 billion per 
year, and accounts for 14% to 17% of hospitalizations in this patient population(2). The 
incidence of thrombotic complications other than renal vein thrombosis in this patient 
population ranges from 8.5% to 44% with an overall incidence of 20%(3). The recent use 
of recombinant erythropoietin (rhEPO) has not generally seemed to change the frequency 
of thrombosis even though it has dramatically reduced the incidence of anemia among 
dialysed patients(4). 
Etiologies for vascular access thromboses in patients on hemodialysis are divided 
into two categories: anatomic and non-anatomic causes. The overwhelming majority of 
anatomic defects consist of graft anastomosis stenosis, specially since the increase in 
utilization of synthetic grafts such as PTFE which are well-known to thrombose more 
commonly than native fistulas with a relative risk estimated in a recent surgical series of 
1.98 over 1 year(5). Non-anatomic etiologies include a variety of systemic disorders, 
including inherited and acquired conditions. These conditions can be inherent to end 
stage renal disease (ESRD), such as hypertensive, diabetic or inflammatory 
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vasculopathies, or occur secondary to hemodialysis treatment, which can itself predispose 
to thrombosis via exposure to additional exogenous factors, loss of plasma proteins to 
dialysate, or poor anticoagulation management before, during, and after dialysis(6,7). 
Non-anatomic etiologies also include a broadly-defined, well-known condition referred 
by the literature as a “hypercoagulable state”. This clinical condition, has remained a 
diagnosis of exclusion when thrombotic events cannot be accounted for by other known 
etiologies. The literature has presented many different laboratory criteria and diagnostic 
tests to characterize this condition, but it still remains loosely defined as “any alteration 
of the coagulation pathways that predisposes to thromboses”(8) largely because it is a 
highly complex, multi-factorial phenomena, whose underlying causes have not been well 
elucidated. Since platelet aggregation plays a major role in thrombus formation, 
antiplatelet agents such as Sunfinpyrazone, aspirin, and dipyridamole have been used 
with encouraging results(9). 
Patients on CAPD, which is now an established form of therapy for ESRD, 
comprising 15% of the total number of patients worldwide on dialysis in 1997(10), have 
also been found to exhibit a hypercoagulable state(ll). Prior studies have not 
characterized hypercoagulability in these patients since thrombosis is not a well-defined 
complication of CAPD. Unlike hemodialysis, which requires the use of heparin without a 
functioning kidney to metabolize it, peritoneal dialysis does not require the use of 
anticoagulant therapy and thus patients are less likely to develop bleeding complications. 
Nevertheless, characterizing hypercoagulability in this patient population could be very 
important since it remains controversial as to whether it places CAPD patients at an 

increased risk for developing atherosclerosis and subsequent coronary artery and 
cerebrovascular disease. 
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Renal transplant recipients on immunosuppressive treatment are also well-known 
to exhibit a hypercoagulable state(12). Roughly 10-20% of kidney grafts are lost during 
the first year post-transplant(13). Acute rejection is the most common cause of rejection, 
but early graft loss due to venous or arterial thrombosis is a well known complication 
with an incidence of 1-7%(14,15). In pediatric patients, thrombosis is an even greater 
issue accounting for about 12% of failed transplant and 20% of failed repeat 
transplant(16). Recently, hypercoagulable states have also been implicated in certain 
forms of acute rejection (14). Biopsy specimens from patients with severe acute rejection 
frequently show intravascular fibrin deposition(17).This finding suggests that a 
hypercoagulable state could be a nonimmunologic factor playing an important role in 
acute rejection, and partly explains why despite the use of aggressive immuno 
suppressive agents, the incidence figures listed above have not decreased significantly 
over the past few years(18). Understanding, diagnosing, and managing 
hypercoagulability in kidney transplant patients could help prevent acute rejection as well 
as other long-term complications. 
Thrombosis and the role of coagulation 
Thrombosis is a multi-factorial, poly-regulated phenomenon that continues to be 
highly debated and controversial. Classically, Virchov’s triad( 19) has been used to 
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describe and compartmentalize the three main etiologic factors that lead to thrombosis: 
endothelial injury, low flow states, and hypercoagulability. As we advance our 
understanding of thrombosis, it has become apparent that these individual compartments 
are highly integrated and cannot be treated as individual clinical processes. Anatomic 
causes for thrombosis can be repaired surgically, underlying systemic conditions such as 
hyperestrogenic states and sickle cell anemia can be managed medically, but 
coagulopathic etiologies remain poorly elucidated, and poorly managed. 
Normal hemostasis displays a delicate balance of ensuring that significant 
breaches in vessel walls are plugged, while at the same time preventing these same plugs 
from causing distal ischemia (Figure 1). This modulation consists of four general 
processes (modified from Robbins(8)): 
1) Platelet activation: 
Following injury to a blood vessel wall, platelets are exposed to endothelial cell 
extracellular matrix (ECM) constituents such as collagen, proteoglycans, fibronectin 
and other adhesive glycoproteins. This exposure causes platelets to adhere to the 
vessel wall and to release of a variety of granules which lead to platelet aggregation 
and subsequent formation of a platelet plug, called primary hemostasis. 
2) Coagulation cascade: 
Platelet granules also activate the coagulation cascade, which represents a series of 
conversions of inactive proenzymes to activated enzymes which culminates in the 
conversion of the plasma soluble fibrinogen into the insoluble fibrous protein fibrin. 

Polymerized fibrin and platelet aggregates form a solid permanent plug that prevents 
further hemorrhage called secondary hemostasis. 
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3) Modulation of the coagulation cascade: 
Endothelial cells have the ability to prevent coagulation via a slew of membrane- 
associated inhibitory factors such as thrombomodulin, antithrombin III, protein C and 
protein S. This inhibitory mechanism, modulates the rate of prothrombotic activity 
and prevents unneccessary thrombosis. 
4) Plasmin mediated fibrinolysis: 
Fibrin deposits are eventually cleared from endothelial surfaces through a process 
called fibrinolysis. This process is mediated via tissue type plasminogen activator (t- 
PA) synthesized by endothelial cells and urokinase-like plasminogen activator present 
in plasma and various tissues. Endothelial cells further modulate 
coagulation/anticoagulation by releasing plasminogen activator inhibitors that block 








+ Exerts a stimulatory effect 
Exerts an inhibitory effect 
EC Endothelial Ceil 
ATIII Antithrombin ill 
tPA Tissue Plasminogen Activator 
uKA Urokinase Activator 
Figure 1 - Modulation of hemostasis in healthy individuals 
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Given the careful balance of forces modulating thrombotic activity, it is clear that 
abnormalities or imbalances in any of these processes could potentially tilt the balance 
towards a hyper or hypocoagulable state. There are several well characterized genetic 
conditions affecting specific hemostatic elements that lead to a hypercoagulable state 
such as factor V mutations, antithrombin III, and proteins C and S deficiencies. The most 
common of these is factor V Leiden mutation (FVL) consisting of a single point mutation 
in the factor V gene with an Arg to Gin transition at position 506 with a prevalence of 6% 
in Caucasian populations(20). It was observed that in patients with this point mutation, 
factor Va was resistant against the anticoagulant action of activated protein C leading to 
prothrombotic manifestations^ 1). In a surgical series, it was found that kidney allograft 
recipients with FVL had a 39% chance of developing venous thrombosis, including 
primary graft thrombosis, compared to a 15% chance in patients without the 
mutation(22). However, genetic risk factors alone do not explain hypercoagulability, and 
must be examined in the context of other prothrombotic conditions affecting 
hemodialysis, CAPD, and renal transplant patients which still remain ill-characterized. 
Etiology of hypercoagulability in hemodialysis, peritoneal dialysis and kidney 
transplant patients 
The literature contains a rich ensemble of studies (see below) exploring several 
different etiologies for hypercoagulability in hemodialysis, peritoneal dialysis and kidney 
transplant patients with limited agreement and elucidation. What follows is a 
comprehensive review of the findings that have helped shape our current understanding 

of hypercoagulability in this population, with particular emphasis on the promising main 
players (Figure 2). 
It is well known that the blood of patients on dialysis undergo protein loss via a 
mechanism resembling the nephrotic syndrome(23). Some papers argue that in addition 
to protein loss via dialysis, there is a significant alteration in the plasma protein content 
secondary to renal failure itself(24). Either way, levels of specific plasma elements get 
modified, break the careful hemostatic balance, and lead to coagulation abnormalities. A 
few studies have attempted to attribute hypercoagulability to abnormal levels of different 
coagulation cascade proteins in this patient population, and the following were described: 
hemodialysis patients had increased levels of factor VII(25), CAPD patients displayed 
increased activity of factors VII and VIII(26), and kidney transplant patients exhibited 
increased factor VII activity(27). 
Other studies have attempted to explain hypercoagulability on the basis of 
antithrombotic protein deficiencies. Decreased levels of protein C have been found in 
CAPD patients(28) as well as increased levels of antithrombin 111(26). In hemodialysis 
patients however, decreased levels of antithrombin III were found(28). These findings 
were supported in another series(29) which actually found that all three antithrombotic 
proteins (antithrombin III and proteins C and S) were more elevated in CAPD patients 
than in hemodialysis patients which was a somewhat equivocal finding since both 
dialysis modalities exhibit protein loss. 
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Abnormalities in fibrinolysis have also been described as a contributing factor to 
hypercoagulability in this patient population(30). Several series looking at t-PA activitity 
have found hyperfibrinolysis in both CAPD and hemodialysis patients (29,31)- These 
studies have argued that the increase in fibrinolytic activity could be a response to a 
decrease in antithombotic substances, representing a backup antithrombotic protective 
mechanism. However, the finding of increased antithrombotic substances in CAPD 
patients(28,29) weakens this argument, which will remain unverified until fibrinolytic 
activity is directly correlated with actual antithrombotic substance levels. Kidney 
transplant patients on the other hand, have been shown to exhibit hypofibrinolysis(12). It 
remains unclear as to whether hypofibrinolysis is a potential primary process underlying 
hypercoagulability in kidney transplant patients. 
In addition to abnormalities in the hemostatic processes, other plasma components 
have been associated with hypercoagulability in dialysis patients. Hyperhomocystenuria, 
a putative risk factor for atherothrombotic cardiovascular disease, was found to confer an 
increased risk for hemodialysis access thrombosis(32). Similarly, abnormal lipid 
metabolism and increased levels of atherogenic lipids, which is also a risk factor for 
coronary artery disease, was found to play a role in hypercoagulability and 
hyperfibrinolysis in CAPD patients (31). The latter finding was followed by a second 
study that looked at lipid reduction therapy as a way to correct hypercoagulability with 
unsuccessful results(33). The exact role of hyperhomocystenuria and abnormal lipid 




More recent studies have noted that dialysis patients with high antiphospholipid 
antibody titers with and without systemic lupus erythematous were found to have more 
frequent access thrombosis than patients with low/negligible titers(34,35). Renal 
manifestations include thrombotic microangiography and large vessel thrombosis which 
is thought to be mediated via an autoimmune response. The mechanism underlying this 
phenomena has not been clearly delineated but it is thought to be caused by 
antiphospholipid antibodies directed against epitopes on oxidized phospholipids 
complexed with a glycoprotein, beta 2-glycoprotein I, or against the glycoprotein itself. 
Antiphospholipid antibodies may increase with time on dialysis, possibly as a result of 
oxidative stress incurred during dialysis(36). Moreover, higher than normal levels of 
antiphospholipid antibodies have also been found in kidney transplant patients(37). It is 
postulated that they are acquired pretransplant and persist in the body postransplant, and 
may help explain hypercoagulability in kidney transplant patients. Treatment of 
antiphospholipid antibody syndrome remains centered around anticoagulation with 
warfarin, since the use of immunosuppressive agents had no dramatic effect on titers and 
on the incidence of thrombotic events(36). 
Hypercoagulability in kidney transplant patients is also thought to occur 
secondary to long-term steroid treatment 12,38). It is suggested that steroid use affects 
the fibrinolytic system, decreasing its activity and hence favoring a prothrombotic state. 
However, the largest prospective trial examining the effect of steroids on coagulation has 
failed to demonstrate a significant difference in thrombotic events between cyclosporine- 
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treated and non-cyclosporine-treated patients(14). Whether steroid use alone explains 
hypofibrinolysis in kidney transplant patients, or whether genetic as well as acquired risk 
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Components in black: Healthy individuals (found in Figure 1) 
Components in red: Abnormalities in coagulation 
+ Exerts a stimulatory effect 
Exerts an inhibitory effect 
EC Endothelial Cell 
ATIII Antithrombin III 
tPA Tissue Plasminogen Activator 
uKA Urokinase Activator 
Figure 2 - Coagulation abnormalities 
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It has been shown that dialysis patients with elevated levels of anti-phospholipid 
antibodies experience a decline in their levels after a renal transplantation(37), suggesting 
that if indeed antiphospholipid antibodies are related to a hypercoagulable state, then 
kidney transplantation should improve the hypercoagulability in dialysis patients. 
However, Prior studies have not quantitatively compared hypercoagulability across 
hemodialysis, CAPD and kidney transplant patients to assess whether either modality of 
dialysis leads to a higher degree of hypercoagulability or whether kidney transplantation 
ameliorates hypercoagulability in dialysis patients. 
Detection and management of hypercoagulability in renal failure: Is it economically 
viable to make it routine? 
Dialysis and renal transplant patients are not routinely screened for 
hypercoagulability given the high costs associated with the tests and the limited evidence 
linking measurable parameters of hypercoagulabity and clinical thrombosis. On the other 
hand, costs associated with vascular access thrombosis and renal allograft thrombosis are 
also high. As mentioned before, these conditions costs the United States over $1 billion 
per year(39). 
A recent study found that the incidence of renal allograft thrombosis could be 
reduced from 4% to 1.5% by anticoagulating renal transplant patients with laboratory 
evidence of hypercoagulability(40). The hypercoagulability panel employed in the study 
included ATIII deficiency, protein S deficiency, protein C deficiency, activated protein C 
/ 
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resistance and anticardiolipin antibodies. Patients with evidence of hypercoagulability 
were heparinized immediately post-op and maintained on Warfarin at a targeted INR of 
2.0-2.5. Based on the successful reduction in the incidence of thrombosis, the authors 
subsequently performed a cost-benefit analysis to compare the costs of testing all renal 
transplant candidates for hypercoagulability with the savings incurred by reducing the 
incidence of allograft thrombosis. Their analysis determined that unless the 
hypercoagulability panel cost under $280, it was not cost-effective to test all candidates 
for hypercoagulability. The hypercoagulability panel employed in the study was 
estimated to cost $2200; an order of magnitude higher than necessary for cost- 
effectiveness. 
Understanding the etiology of hypercoagulability would enable the development 
of more sensitive tools that could be used routinely to better manage renal failure 
patients. Increased sensitivity would theoretically enable a stronger reduction in the 
incidence of thrombosis which in turn, would allow more costly tests to achieve cost- 
effectiveness. 

Thromboelastography and Sonoclot analysis as viscoelastic monitors of 
hypercoagulability in hemodialysis, peritoneal dialysis and kidney transplant 
patients 
15 
Studies looking at coagulation have for the most part analyzed individual assays 
of hemostatic components such as coagulation cascade factors, fibrinogen, antithrombotic 
substances, t-PA activity, fibrin degradation products among others. Lately, they have 
also included sophisticated assays of components such as proteins C and S activities, 
protein C resistance, factor II assays and antiphospholipid assays which include lupus 
anticoagulant, anticardiolipin antibodies and antiphosphatidyl serine antibodies(7). 
Coagulation studies also commoly describe hypercoagulability on the basis of 
abnormalities in prothrombin time (PT) and activated partial thromboplastin time (aPTT). 
Whereas these measurements are very effective screens for abnormal clotting, these tests 
only provide particular end-points in coagulation, and terminate when fibrin strands are 
formed. Each of these tests measure different components of coagulation, and even 
together, do not provide a comprehensive picture of the clotting process(41). In trying to 
understand coagulation abnormalities, which involves a complex array of interconnected 
factors, it would be more informative to obtain a comprehensive dynamic profile of a 
developing clot all the way from fibrin formation to clot dissolution. 
Thromboelastography (TEG) and sonoclot analysis (SCT) are viscoelastic 
monitoring of blood clotting that provide a dynamic profile of coagulation. The basic 
principle involves the application of a mechanical force to coagulating blood, and 
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detecting the response(42). In other words, as coagulation begins, fibrin monomers 
linearly associate to form fibers and these subsequently cross link with each other and 
with red blood cells and platelet to form a clot. As this clot starts to develop, it becomes 
an obstacle for flow and its viscosity increases. If a mechanical force is applied to this 
developing clot, as viscosity increases there is increasing resistance to that force until it 
reaches a maximum when the clot is fully formed. As fibrinolysis commences, the clot 
begins to dissolute, the viscosity starts to decrease, and the resistance to flow drops 
accordingly. Thus, viscoelastic monitors such as TEG and SCT detect the liquid-to-solid 
transition of an evolving clot and provide a comprehensive profile of this transition rather 
than at end-points as in routine coagulation tests. 
In TEG, 0.36ml of blood is placed into a TEG cuvette immediately following 
phlebotomy. A piston is lowered into the cuvette and as the cuvette is rotated back and 
forth around the piston, the increase in viscosity is transmitted through a torsion wire to a 
recording device that generates a curve over time. Figure 3 illustrates the TEG process 
and provides an explanation of the recorded indices. Figure 4 demonstrates the typical 
TEG pattern in the normal physiologic state and Figure 5 demonstrate the typical TEG in 
hypercoagulability. The TEG allows not only close monitoring of clot formation, but also 
gives great insight as to the activity of the fibrinolytic system(42). 
In SCT, a hollow open-ended plastic probe mounted on a transducer is allowed to 
vibrate vertically while immersed in 0.4ml of fresh clotting blood. The viscous drag on 
the probe, impeding its free vibration, is detected by the electronic circuits driving the 
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probe and is converted to an output signal that is recorded on a paper chart. Figure 6 
illustrates the SCT process and provides an explanation of the recorded indices. Figure 7 
demonstrates the typical SCT pattern in the normal physiologic state and Figure 8 
demonstrated the typical SCT signature in hypercoagulability (41). 
The mechanical distinction between TEG and SCT is that TEG measures the 
torsional impedance imparted to a fixed piston suspended in a rotating cuvette of 
coagulating blood, whereas SCT measures the changes in impedance to movement of a 
vibrating probe in a developing clot (41). 
TEG and SCT analysis have been shown to be superior over individual assays of 
hemologic components(43), particularly in detection and monitoring of the 
hypercoagulable state(44). The clinical usefulness of the TEG and Sonoclot analyzer is 
evidenced by its increased utilization for perioperative coagulation assessment in patients 
undergoing cardiopulmonary bypass and liver transplantation (41,45). 
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r Rate of thromboplastin generation 
Time taken for the TEG amplitude to reach 2mm. It is a function of 
thromboplastin generation and the intrinsic coagulation system. 
r+k Coagulation time 
Time taken for the TEG amplitude to reach 20mm (i.e. clot of a certain strength). 
It is a function of the intrinsic coagulation system, platelets, and fibrinogen. 
MA Maximum amplitude 
Largest amplitude of the TEG. It is a function of clot strength. Improved quality 
of platelets, fibrinogen, and factor XIII increase MA. 
Ang Clot formation rate 
Rate of formation of a solid clot. It is a function of fibrinogen and platelet quality. 
LY30 Fibrinolysis at 30 minutes 
percentage decrease in TEG amplitude relative to MA at 30 minutes. 
LY60 Fibrinolysis at 60 minutes 
Percentage decrease in TEG amplitude relative to MA at 60 minutes. 
Figure 3 - Schematic of indices recorded on TEG. Figure 4 and Figure 5 on proceeding 
pages show TEG of actual patients 
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10 mm R (mm) K (mm) MA (mm) Ang (deg) 
scale Pt: 6.5 4.0 62.0 66.5 
Figure 4 - TEG of a control patient 
LV30 (x) LY60 (x) 
2.0 5.5 
10 mm R (mm) K (mm) MA (mm) Ang (deg) LV30 ('/) LV60 (x) 
scale Pt: 4.5 1.5 83.0 80.5 0.0 0.0 
Figure 5 - TEG of a hypercoagulable patient. Hypercoagulability is demonstrated by 
an elevated clot strength (MA) and rate of clot formation (Ang) while impaired 
fibrinolysis is demonstrated by a lowered percent fibrinolysis at 30 and 60 minutes 




SonACT Activation time 
Time in seconds to the beginning of fibrin formation, defined as a 1mm 
upward deflection in the SCT signature. 
SonR Rate of fibrin formation 
Rate of solid clot formation which is directly proportional to the increase 
in viscosity. 
Figure 6 - Schematics of indices recorded on SCT 
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Figure 7 - SCT of a control patient 
Figure 8 - SCT of a hypercoagulable patient. Hypercoagulability is demonstrated by a 
shorter clot activation time (SonACT) and by an elevated rate of fibrin formation (SonR). 

STATEMENT OF PURPOSE 
This study seeks to introduce thromboelastography (TEG) and sonoclot analysis 
(SCT) in the evaluation of hypercoagulability in hemodialysis, peritoneal dialysis, and 
kidney transplant patients. Most of the studies looking at coagulation in this patient 
population have used prothrombin time (PT), activated partial thromboplastin time 
(aPTT), protein levels, and assays of isolated haemostatic components to measure 
hypercoagulability. TEG and SCT were employed in this study since their measures of 
whole blood clotting and rheological properties in assessing hypercoagulability, have 
been demonstrated to be superior over assays of individual hematologic 
components(43,44). 
The puiposes of this study are threefold: 
(1) to confirm a hypercoagulable state in hemodialysis, peritoneal dialysis and 
renal transplant patients compared to controls using thromboelastography 
(TEG) and sonoclot analysis (SCT); 
(2) to compare hemodialysis and peritoneal dialysis patients; 
(3) to determine whether the hypercoagulable state in dialysis patients is 
significantly corrected in kidney transplant patients; and 
(4) to assay whether hypercoagulability in hemodialysis, peritoneal dialysis, and 






From June 1998 to October 1998, 54 patients of Yale/New Haven Hospital 
volunteered to participate in this study and another 20 healthy volunteers participated as 
controls. The study participants were subsequently placed in one of four study groups 
accordingly: hemodialysis patients (N=21), CAPD patients (N=13), renal transplant 
patients (N=20) and healthy controls (N=20). There were 9 males and 12 females in the 
hemodialysis group with a mean age of 53 (range 11-74 years). There were 9 males and 
4 females in the CAPD group with a mean age of 44 (range 35-61 years). There were 10 
males and 10 females in the renal transplant group with a mean age of 49 (range 27 - 70 
years) and 13 males and 7 females in the control group with a men age of 30 (range 19 - 
58 years). Transplant patients had a mean cholesterol level of 241 (range 136-320), a 
mean triglyceride level of 207 (range 68-573), and had stable renal function (mean 
creatinine of 1.8 with a range 0.7-2.8). 
All subjects were in stable condition. Exclusion criteria for all patients included 
any anticoagulant medication, and/or history of clinical hypercoagulability or active 
bleeding. Samples from hemodialysis patients were not obtained within 4 hours of a 
dialysis session. Phlebotomies in hemodialysis patients were done via peripheral veins. 
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All transplant patients were on different combinations of immunosuppressive 
therapies and were not within 3 months of a rejection period. 
Blood sampling and data collection 
Ten milliliters of blood were collected into vacutainer tubes for evaluation. PT, 
INR and PTT were measured using the HEMOCHRON, JR. Platelet count and 
Hematocrit were determined using a Coulter MD16. 
Whole blood coagulation was determined in a computerized 
thromboelastograph™. Within 5 minutes of phlebotomy, 1 ml of whole blood was 
pipetted into a 1% celite suspension cup. The contents of the cup were then transferred to 
a CaCli suspension. Following the transfer, 0.36 ml of the new mixture was pipetted into 
the thromboelastograph cuvette. The analyzer pin was then lowered into the cuvette. 
Mineral oil was placed on the surface of the sample to eliminate the blood-air interface 
and prevent drying during analysis. The coagulation process was recorded by computer. 
Recorded indices were R time (rate of thromboplastin generation), R+K time 
(coagulation time), alpha angle (rate of clot formation), maximum amplitude (clot 
strength) and % fibrinolysis at 30 and 60 minutes (refer to Figure 1 for explanation of 
TEG indices recorded. Refer to appendix for sample elastograph). 
Whole blood coagulation was also determied using the SIENCO Sonoclot™ 
Coagulation and Platelet Function Analyzer. Within 5 minutes of phlebotomy, 1 ml of 

25 
whole blood was pipetted into a cuvette containing powdered celite. Immediately before 
analysis, a new plastic probe was inserted into the head and lowered into the cuvette. The 
coagulation process was recorded on thermo-sensitive paper. Recorded sonoclot indices 
included SonACT (fibrin formation time) and Scr (rate of fibrin formation) (refer to 
figure 3 for explanation of Sonoclot indices recorded. Refer to appendix for sample 
sonoclot recording). 
5 ml of whole blood was centrifuged and the plasma was sent away for AT III 
levels. 
Statistical analysis 
Gender across the different study groups was compared with the Pearson chi- 
square test. Relationships between ATIII, platelet levels and hematocrit across all groups 
were assessed using Pearson Correlations. Relationships between TEG parameters and 
SCT parameters were also assessed using Pearson Correlations. General Linear Model 
(GLM) and multiple comparison contrast were used to assess continuous variables for 
multiple intergroup comparisons(control vs. PD, control vs. HD, control vs. TXP, TXP 
vs. HD and TXP vs PD). General Linear Model (GLM) and multiple comparison contrast 
were also used to assess continuous variables in men only for intergroup comparisons 
followed by female only analysis. P values reported on the GLM table are based on GLM 
and multiple comparison contrast except for gender which is based on chi-square. Values 





Hematocrit values were significantly higher in the control group (p<0.00001) and in the 
transplant group (p<0.01) than in hemodialysis (HD) or peritoneal dialysis (PD) groups. 
Male hematocrit values were only significantly higher that females in the control group 
(males 42.413.1 ,n=13; females 37.413.8,n=7; p<0.02). In all other groups there were no 
significant differences. 
Platelet levels: 
There were no significant intergroup differences in platelet level. However, when 
correlated with TEG and SCT indices, platelet levels were strongly correlated with MA 
(i~0.349, p=0.0022) and with Ang (r=0.333, p=0.0037). There were no significant 
correlations between platelet level and Age, Hct, PT, INR, PTT or any other TEG or SCT 
indices. 
Gender differences in coagulation: 
For the most part, there were no significant gender differences in coagulation within the 
different groups with the exception of a few parameters that recorded significantly faster 
coagulation in females. In the control group, females had a significantly lower PTT 
(females 31.512.42; males 34.6112.89; p<0.03), higher MA (females 68.113.0; males 
62.615.4; p<0.01), and lower SCr (females 103115.6; males 126116; p<0.02). In the PD 
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group, females also had a significantly lower PTT (females 29.23±2.71,n=4; males 
35.89±5.40,n=7; p<0.02). 
Conventional coagulation tests: 
PT and INR was significantly higher in HD patients than in controls (PT: control 
14.0±1.2; HD 18.1±4.2; p<0.0009; INR: control 1.1±0.1; HD 1.4±0.3; p<0.001). There 
were no other intergroup differences in PT and INR. There were also no significant 
differences in PTT. 
TEG: 
HD and PD patients had a significantly higher MA (clot strength; pcO.OOl) and Ang (clot 
rate; p=0.006) by TEG than either control or Txp patients. K (coagulation time) was 
significantly higher in hemodialysis patients than in transplant patients (p=0.010), and 
LY60 (% lysis at 60 minutes) was significantly lower in PD patients than in controls. 
When controlling for Pit, differences remain significant (p=0.064 for K, p=0.001 for MA, 
p—0.0012 for ANG and p=0.01 for LY60). Differences also remain significant when data 
is controlled for Hct (p=0.02 for K, p=0.03 for MA and p=0.01 for ANG) with the 
exception of LY60 which loses its significance. 
SCT: 
HD patients had a significantly higher SCr (rate) than controls (p<0.001). No other 
groups demonstrated significant differences in SCr and after being controlled for HCT or 

PLT the differences between HD and controls also lost their significance. Sco (onset) was 
not significantly different across the different study groups. 
TEG correlated with SCT: 
TEG parameters correlated with SCT parameters revealed the following significant 
relationships: SCT parameter SCr was strongly correlated with TEG parameters MA 
(r=0.4), Ang (r=0.324) and LY60 (r=-0.3) and SCT parameter Sco was strongly 
correlated with TEG parameters R+K (r=0.31) and MA (r=0.35). 
ATIII: 
There were no significant intergroup differences in AT III levels. However, ATIII levels 
were significantly correlated with Hct (r=0.35; p=0.0026), PT (r=-0.2; p=0.0346), and the 




Table 1: Characteristics of study groups 
Controls Peritoneal Hemodialysis Transplant 
dialysis 
N 20 13 21 20 
Percent male 65.0% 69.2% 42.9% 50% 
Age 30.0 ± 11 43.6 ±8.4 52.8 ± 18.6 48.6 ± 14.4 










Hematocrit 40.6 ±4.1 30.7 ±4.6 31.2 ± 4.4 33.7 ±6.0 < 0.001 a,b,c 
Platelet count 225.1 ±58.5 200.6 ± 77.4 182.5 ±81.8 185.7 ±94.3 0.317 
PT 14.0 ± 1.2 16.5 ±2.3 18.1 ±4.2 16.0 ±3.6 <0.001 b 
INR 1.1 ±0.1 1.3 ±0.2 1.4 ±0.3 1.2 ±0.3 <0.001 b 
PTT 33.5 ±3.1 33.7 ±5.6 34.3 ±9.7 31.5 ±3.7 0.413 
p value comparison: a= C vs PD, b= C vs HD, c= C vs Txp, d= H D vs Txp, e= PD vs Txp 
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Table 3: Comparison of TEG parameters across study groups 
TEG Controls Peritoneal Hemodialysis Transplant P value 
Parameters (C) dialysis (PD) (HD) (Txp) 
R 9.0 ±4.2 9.9 ±4.0 8.0 ±2.5 11.5 ±6.3 0.358 
R+K 12.3 ±5.7 12.5 ±4.8 10.4 ±2.8 15.3 ±8.3 0.289 
MA 64.5 ±5.4 77.2 ±4.2 73.4 ±6.9 66.5 ± 13.8 <0.001 a,b,e 
Ang 68.3 ±8.8 74.1 ±5.6 74.6 ±4.7 64.1 ± 14.3 0.006 d,e 
FY30 2.1 ± 1.8 0.7 ±0.9 1.3 ± 1.3 1.5 ± 1.9 0.036 
FY60 5.8 ±3.8 2.5 ±2.2 3.2 ±2.7 3.4 ± 3.3 0.014 a 
TEG Parameters: r= rate of thromboplastin generation; r+k= coagulation time; MA= maximum 
amplitude; Ang= clot formation rate; LY30 and FY60= fibrinolysis at 30 and 60 minutes (see 
Figure 3). 
P value comparisons: a = C vs PD; b = C vs HD; c = C vs Txp; d = HD vs Txp; e - PD vs Txp 
Table 4: Comparison of SCT parameters across study groups 
SCT Controls Peritoneal Hemodialysis Transplant P value 
Parameters (C) dialysis (PD) (HD) (Txp) 
SonACT 118.8 ± 19.2 145.4 ±35.8 142.6 ±41.9 127.6 ±24.9 0.019 
SonR 16.3 ±4.3 32.4 ± 16.9 33.5 ±29.3 24.5 ±7.8 <0.001 b 
SCT Parameters: SonACT= activation time; SonR= Rate of fibrin formation (see Figure 6) 
P value comparisons: a = C vs PD; b = C vs HD; c = C vs Txp; d - HD vs Txp; e = PD vs Txp 
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Table 5: Comparison of ATIII levels across study groups 
Controls Peritoneal Hemodialysis Transplant P value 
(C) dialysis (PD) (HD) (Txp) 
ATIII levels 84.6 ± 19.4 69.7 ± 20.6 68.7122.0 70.4 ± 22.3 0.049 




TEG and SCT in this study confirm the hypercoagulable state described in 
hemodialysis and peritoneal dialysis patients(l,23,24). Other studies have described this 
prothrombotic tendency using prothrombin time (PT), activated partial thromboplastin 
time (aPTT), protein levels, and assays and activities of isolated haemostatic 
components(25,26,27). We employed TEG and SCT in this study since their measures of 
whole blood clotting and rheological properties in assessing hypercoagulability have been 
demonstrated to be superior over assays of individual hemologic components (43,44). 
TEG and SCT in this study also demonstrate that kidney transplant patients are 
significantly less hypercoagulable than patients in either dialysis groups, which suggests 
that kidney transplantation ameliorates the hypercoagulability found in ESRD patients on 
dialysis. 
Several studies have attempted to characterize the underlying perpetrators of the 
hypercoagulable state without too much agreement nor elucidation. This study sheds new 
light on the following factors proposed by the literature to promote thrombosis: 
AT III levels: 
The literature displays contradictory findings as to the role of ATIII levels in 
hypercoagulability(3,46). In our study, ATIII levels were lower in HD and PD patients 
than in controls, which could help explain hypercoagulability in dialysis patients. 
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However, Txp patients were also found to exhibit equally low ATIII levels despite being 
less hypercoagulable than dialysis patients (according to other parameters recorded) 
which suggests that the coagulation amelioration found in transplant patients cannot be 
explained by ATIII levels alone. We conclude from these findings that while lower ATIII 
levels may weakly contribute to a hypercoagulable state, it is not the sole culprit. 
Antiphospholipid antibodies: 
Recent studies have suggested that antiphospholipid antibody levels may play a role in 
hypercoagulability in dialysis patients(34). It has been further shown that the levels of 
antiphospholipid antibodies present in dialysis patients decline after kidney 
transplantation(37). If antiphospholipids antibodies are indeed proven to be responsible 
for promoting a hypercoagulable state, then their decrease following kidney 
transplantation would help explain why coagulation after kidney transplantation is 
ameliorated as demonstrated by this study. 
Anemia: 
Hematocrit was lower in HD and PD patients than in both controls and kidney transplant 
patients which is an anticipated consequence of decreased erythropoietin secretion by the 
kidneys secondary to renal failure, and solute dilution by the dialisate. Anemia has been 
ruled out as a causative agent promoting hypercoagulability by studies that have 
demonstrated that while the increase usage of rhEPO amongst dialysis patients has 
significantly decreased anemia, it has not changed the incidence of thrombosis(4). 
Nevertheles, HCT in our study was strongly correlated with ATIII levels (r=0.35) which 
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suggests some biochemical connection between red blood cell and ATIII production. 
Whereas rhEPO may correct low HCT found in ESRD it may not correct levels of other 
coagulation factors that may be indirectly linked to red blood cell production. 
Fibrinolysis: 
Several studies looking at t-PA activitity have found hyperfibrinolysis in both CAPD and 
hemodialysis patients (29,31)- Other studies have described a hypofibrinolytic state in 
kidney transplant patients(12). This study however, did not confirm these findings. It 
found no significant differences in fibrinolysis across the different study groups, with the 
exception of HD patients, who actually exhibited hypofibrinolysis when compared to 
controls. This contradiction may be partially explained by assay differences used to 
measure fibrinolysis: past studies measure t-PA activity and fibrin-split products, whereas 
TEG measures clot strength decreases over time as the clot within the TEG cuvette lyses, 
which provides a more direct measurement of fibrinolytic activity(42). Either way, it has 
been suggested that dialysis patients may experience an increased fibrinolytic activity as 
a response to decreased antithrombotic activity, which will remain unverified until 
fibrinolytic activity is directly correlated with actual levels/activity of antithrombotic 
substances in dialysis and kidney transplant patients. 
Platelet count: 
It is well known that in conditions where platelet levels are low or platelet activity is 
impaired, bleeding diatheses occur. Whereas no significant differences in platelet levels 
were found across different groups, there were strong correlations between platelet levels 
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and TEG indices in all groups, suggesting that platelet levels may contribute to 
hypercoagulability. However, even after the data was corrected for platelet count, HD 
and PD patients were hypercoagulable when compared to control patients suggesting that 
if platelet levels do indeed contribute to hypercoagulability, they are not the sole culprits. 
Relative platelet activity within the different study groups, which was not within the 
scope of this study, would be a useful measure to obtain in future studies investigating the 
role of platelets in hypercoagulability. 
In addition to the factors included above, there are a several other 
substances/parameters that have been studied in order to explain hypercoagulability in 
dialysis patients. These studies have not found a strong association between any of these 
components and a hypercoagulable state which can only mean one of three things: 
1. No study has effectively demonstrated which single hemostatic component is 
the best predictor of coagulation complications 
2. Despite the variety of plasma components currently being investigated for 
their link to hypercoagulability, there could be other components that have not 
yet been identified. 
3. Given the fact that no single component is a good predictor of coagulation 
complications, it is very likely that the underlying cause of hypercoagulability 
in this patient population may be a combination of possible culprits acting in 
unison. 
This study, for example, was not able to strongly correlate ATIII levels to TEG or SCT 
indices, but the possibility still remains that ATIII levels may underlie hypercoagulability 
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in some of the patients in the study whereas other patients demonstrate 
hypercoagulability secondary to other factors such as antiphospholipid antibodies. If that 
were the case, this study would have had to look at correlations between TEG/SCT 
indices and low ATIII/high antiphospholipid antibodies at the same time. In addition, 
there are genetic risk factors that can predispose any one of the conditions above and lead 
to variability in these studies. Only by collecting data on all potential plasma components 
identified by the literature as possibly playing a role in hypercoagulability, and 
performing multivariate analysis to compare them with TEG and SCT profiles would 
such complex multi-factorial correlations be found. Medicine classically attempts to find 
one answer that explains several phenomena, but given the complexity of coagulation and 
the years of unsuccessful pursuit for a single culprit to explain hypercoagulability, it 
might be time to pursue multi-factorial answers. Due to the increase in shortage of 
organs, screening of genetic and acquired risk factors for hypercoagulability needs to be 
considered to stratify risk and allow rational intervention. 
Since TEG and SCT provides a comprehensive picture of coagulation regardless 
of underlying culprits, they could be used to predict the risk of renal allograft rejection 
and thrombosis in transplant candidates. If a correlation is demonstrated between TEG 
and SCT tracings and the risk of rejection and thrombosis then transplant candidates with 
hypercoagulable tracings could be prophilactically anticoagulated post-op. 
The seemingly more rapid coagulation in females as evidenced by PTT, MA and 
SCr in the control group and PTT in PD group is consistent with findings by Francis et 
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al.(47) who used TEG and SCT to investigate hypercoagulability in cancer patients. This 
gender difference cannot be explained by the scope of this experiment and requires 
further investigation. 
Finally a few words about TEG and SCT. Several parameters of TEG and SCT 
were well correlated with each other in this study which confirms the validity of these 
tests as accurate monitors of coagulation. Whereas we recommend the use of TEG and 
SCT in future studies investigating coagulation abnormalities, we also have a few words 
of caution. While TEG and SCT manuals recommend analysis within 5 minutes of 
phlebotomy, parameters that monitor the onset of clotting(R and R+K in TEG and 
SonACT in SCT) will differ significantly if blood samples are analyzed 5 minutes as 
opposed to 30 seconds after sampling. The same holds true for measures of PT, INR and 
PTT using the HEMOCHRON, JR analyzer. It was no surprise that these parameters 
were not reliably statistically significant after data analysis. We therefore recommend that 
investigators attempt to analyze blood at a constant set point, say 2 minutes after 
phlebotomy, so that variation is minimized and that the machine be placed in a 
centralized location, for easy access from all sample collection stations. 
In summary, this study utilized TEG and SCT to confirm that a hypercoagulable 
state is present in hemodialysis and peritoneal dialysis patients, and to demonstrate that 
kidney transplantation ameliorates the hypercoagulability found in dialysis patients. 
ATIII levels could not account for the amelioration observed in this study and other 





attempting to identify with confidence the underlying causes of hypercoagulability need 
to assay levels and activity of all potential culprits suggested by the literature, and 




1. Rabelink T.J., Zwaginga J.J., Koomans H.A., et al. 1994. Thrombosis and 
hemostasis in renal disease. Kidney Int. 46:287-296. 
2. DeMarchi S, Cecchin E, Failed E, et al. 1997. Long-term effects of erythropoietin 
therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in 
hemodialysis patients. Soc. Nephrol. 8:1147-1156. 
3. Llach F, et al. 1985. Hypercoagulability, renal vein thrombosis, and other 
thrombotic complications of the nephrotic syndrome. Kid. Inti. 28:429-439. 
4. Kaupke C.J., Butler G.C., Vaziri N.D. 1993. Effect of recombinant human 
erythropoietin on platelet production in dialysis patients. J. Am. Soc. Nephrol. 
3:1672-9. 
5. Culp K, Flanigan M, Taylor L, Rothstein M. 1995. Vascular access thrombosis in 
new hemodialysis patients patients. Am. J. Kidney. Dis. 26:341-346. 
6. Vaziri N.D., Branson H.E., Ness R. 1980. Changes of coagulation factors IX, 
VIII, VII, X and V in nephrotic syndrome. Am. J. Med. Sci. 280:167-171. 
7. Lesar C.J., Merrick H.W., Smith M.R. 1999. Thrombotic complications resulting 
from hypercoagulable states in chronic hemodialysis vascular access. J. Am. Coll. 
Surg. 189:73-81. 
8. Robbins S.L., Kumar V, Cotran R.S. 1997. Basic Pathology. 6th edition. WB 
Saunders Company. 
9. Del Greco F, Soper W.S., Krumlovsky F.A., et al. 1989. Thrombosis of vascular 
access for haemodialysis. In Haemostasis and the Kidney. G. Remuzzi, E.C. 
Rossi, editors. London: 303-308. 

40 
10. Gokal R, Mallick N.P. 1999. Peritoneal Dialysis [Seminar], The Lancet 353:823- 
828. 
11. Kobayashi M, Yorioka N, Yamakido M. 1997. Secondary hypercoagulability and 
secondary hyperfibrinolysis may be related to abnormal lipid metabolism in 
patients treated with continuous ambulatory peritoneal dialysis. Nephron. 76:56- 
61. 
12. Patrassi G.M., Sartori M.T., Rigotti P, et al. 1995. Reduced fibrinolytic potential 
one year after kidney transplantation. Relationship to long-term steroid treatment. 
Transplant. 59:1416-20. 
13. Heidenreich S, Nowak-Gottl U, August C, et al. 1999. Hypercoagulable state and 
graft rejection - is there a link?. Nephol. Dial. Transplant. 14:2293-2296. 
14. Gruber S.A., Chavers B, Payne W.D. et al. 1989. Allograft renal vascular 
thrombosis. Transplant. 47:475-478. 
15. Irish A. 1999. Renal allograft thrombosis: can thrombophilia explain the 
inexplicable? Nephrol. Dial. Transplant. 14:2297-2303. 
16. Singh A, Stablein D, Tejani A. 1997. Risk factors for vascular thrombosis in 
pediatric renal transplantation. Transplant. 63:1263-1267. 
17. Tsuchida A, Salem H, Thomson N, et al. 1992. Tumor necrosis factor production 
during human renal allograft rejection is associated with depression of plasma 
protein C and free protein S levels and decreased intagraft thrombomodulin 
expression. J. Exp. Med. 1992; 175:81. 

41 
18. Sol linger H.W. 1995. Mycophenolate mofetil for the prevention of acute rejection 
in primary cadaveric renal allograft recipients. U.S. Renal Transplant 
Mycophenolate Mofetil Study Group. Transplant. 1995;60:225. 
19. Virchov R. 1856. Phlogose und thrombose, in Virchov R (ed): Gesammelte 
Abhandlungen zur Wissenschaftlicgen Medicin. Frankfurt, Germany, Von 
Meidinger Sohn. 458pp. 
20. Berina R.M., Koeleman B.P., Koster T et al. 1994. Mutation in blood coagulation 
factor V associated with resistance to activated protein C. Nature 369:64-67. 
21. Dahlback B, Carlsson M, Stevensson P.J. 1993. Familial thrombophilia due to a 
previously unrecognized mechanism characterized by poor anticoagulant response 
to activated protein C: prediction of a cofactor to activated protein C. Proc. Natl. 
Acad. Sci. USA 90:1004-1008. 
22. Irish A.B., Green F.R., Gray D.W.R., Morris P.J. 1997. The factor V Leiden 
(R506Q) mutation and risk of thrombosis in renal transplant recipients. 
Transplant. 64:604-607. 
23. Bertoli M, Gasparotto M.L., Vertolli U, et al. 1984. Does hypercoagulability exist 
in CAPD patients? Perit. Dial. Bull. 4:237-239. 
24. Ambuhl P.M., Wuthrich R.P., Korte W, et al. 1997. Plasma hypercoagulability in 
haemodialysis patients: impact of dialysis and anticoagulation. Nephrol. Dial. 
Transpl. 12:2355-64. 
25. Irish A.B., Green F.R. 1998. Factor VII coagulant activity (Vile) and 
hypercoagulability in chronic renal disease and dialysis: relationship with 

42 
dyslipidaemia, inflammation, and factor VII genotype. Nephrol. Dial. Transplant. 
13:679-684 
26. Jones C.L., Andrew M, Eddy A, et al. 1990. Coagulation abnormalities in chronic 
peritoneal dialysis. Ped. Nephrol. 4:152-5. 
27. Irish A.B., Green F.R. 1997. Environmental and genetic determinants of the 
hypercoagulable state and cardiovascular disease in renal transplant recipients. 
Nephrol. Dial. Transpl. 12:167-73. 
28. Alegre A, Vicente V, Gonzalez R, et al. 1987. Effect of hemodialysis on protein C 
levels. Nephron. 46:386-7. 
29. Alwakee J, Gader A.M., Hurieb S, et al. 1996. Coagulation inhibitors and 
fibrinolytic parameters in patients on peritoneal dialysis and hemodialysis. Intern. 
Urol. & Nephrol. 28:255-61. 
30. Assouad M, Eknoyan G. 1998. Does the choice of renal replacement adversely 
affect the hypercoagulability associated with renal disease. Amer. Jour, of 
Nephrol. 18:175-8. 
31. Kobayashi M, Yorioka N, Yamakido M. 1997. Hypercoagulability and secondary 
hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated 
with continuous ambulatory peritoneal dialysis. Nephron. 76:56-61. 
32. Shemin D, Lapane K.L., Bausserman L, et al. 1999. Plasma total homocysteine 
and hemodialysis access thrombosis: a prospective study. Joum. of the Amer. Soc. 
of Nephrol. 10:1095-9. 
33. Kario K, Matsuo T, Hoshide S, et al. 1999. Lipid-lowering therapy corrects 
endothelial cell dysfunction in a short time but does not affect hypercoagulable 

43 
state even after long-term use in hyperlipidemic patients. Blood Coag. & Fibrinol. 
10:269-76. 
34. Brunet P, Aillaud M, Marco M.S., et al. 1995. Antiphospholipids in hemodialysis 
patients: relationship between lupus anticoagulant and thrombosis. Kidney Int. 
48:794-800. 
35. Prakash R, Miller C.C. Ill, Suki W.N. 1995. Anticardiolipin antibody in patients 
on maintenance hemodialysis and its association with recurrent arteriovenous 
graft thrombosis. Am. J. Kidney Dis. 26:347-352. 
36. Joseph R.E., Radhakrishnan J, Appel G.B. 2001. Antiphospholipid antibody 
syndrome and renal disease. Curr. Opin. Nephrol. Hypertens. 10:175-181. 
37. Ducloux D, Pellet E, Fournier V, et al. 1999. Prevalence and clinical significance 
of antiphospholipid antibodies in renal transplant recipients. Transplant. 67:90-3. 
38. Patrassi G.M., Sartori M.T., Livi U, et al. 1997. Impairment of fibrinolytic 
potential in long-term steroid treatment after heart transplantation. Transplant. 
64:1610-4. 
39. DeMarchi S, Cecchin E, Failed E, et al. 1997. Long-term effects of erythropoietin 
therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in 
hemodialysis patients. Soc. Nephrol. 8:1147-1156. 
40. Friedman G.S., Meier-Kriesche H, et al. 2001. Hypercoagulable states in renal 
transplant candidates: impact of anticoagulation upon incidence of renal allograft 
thrombosis. Transplant. 2001:1073-1078. 
41. Hett D.A., Walker D, Pilkington S.N., et al. 1995. Sonoclot analysis. Br. J. 
Anaesthesia. 75:771-776. 

42. Riha P, Stolz, J.F. 1997. Coagulation and hemorheology. Clin. Hemorheol. and 
Microcirc. 17:251-259. 
44 
43. Tuman K.J., Spiess B.D., McCathy R.J., et al. 1989. Comparisson of viscoelastic 
measures of coagulation after cardiopulmonary bypass. Anesth. Analg. 69:69-75. 
44. Peck S.D. 1979. Evaluation of the in vitro detection of the hypercoagulable state 
using the hrombin generation test and plasma clot impedance test. Thromb. and 
Haemost. 42:764-777. 
45. Mallet S.V., Cox D.J.A. 1992. Thromboelastography. Br. J Anaesthesia. 69:307- 
313. 
46. Bayston T.A., Lane D.A., et al. 1997. Antithrombin: molecular basis of 
deficiency. Thromb. and Hemost. 78:339-343. 
47. Francis J.L., Francis D.A., et al. 1994. Assessment of hypercoagulability in 
patients with cancer using the sonoclot analyzer and thromboelastography. 





HARVEY CUSHING/JOHN HAY WHITNEY 
MEDICAL LIBRARY 
MANUSCRIPT THESES 
Unpublished theses submitted for the Master’s and Doctor’s 
degrees and deposited in the Medical Library are to be used only with 
due regard to the rights of the authors. Bibliographical references 
may be noted, but passages must not be copied without permission of 
the authors, and without proper credit being given in subsequent 
written or published work. 
This thesis by 
has been used by the following person, whose signatures attest their 
acceptance of the above restrictions. 
NAME AND ADDRESS DATE 
J) YALE MEDICAL LIBRARY 
3 9002 01037 7456 

